Steven Cohn

Emailsmcohn@utmb.edu

Research activity per year

If you made any changes in Pure these will be visible here soon.

Fingerprint

Dive into the research topics where Steven Cohn is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

6 Similar Profiles

1 Completed
7 Active

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo and Active Controlled, Treat-Through study to Evaluate the Efficacy and Safety of Mirikizumab in Patients with Moderately to Severely Active Crohn's Disease
Cohn, S.
8/20/20 → 8/19/22
Project: Other project
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo and Active Controlled, Treat-Through study to Evaluate the Efficacy and Safety of Mirikizumab in Patients with Moderately to Severely Active Crohn's Disease
Cohn, S.
Eli Lilly
8/20/20 → 8/19/22
Project: Other project
Protocol I6T-MC-AMBG (a) A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis - LUCENT 2
Cohn, S.
5/13/20 → 5/12/25
Project: Other project
Protocol I6T-MC-AMBG (a) A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis - LUCENT 2
Cohn, S.
Eli Lilly & Company
5/13/20 → 5/12/25
Project: Other project
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients with Moderately to Severely Active Ulcerative Colitis.
Cohn, S.
2/27/20 → 2/26/25
Project: Other project

2064 Citations
25 h-Index
39 Article
2 Chapter
1 Review article

AIDS-associated Esophageal Plasmablastic Lymphoma
Abdulla, H. M. & Cohn, S., Jan 2021, In: Clinical Gastroenterology and Hepatology. 19, 1, p. A18
Research output: Contribution to journal › Article › peer-review
Fibroblast growth factor receptor-3 (FGFR-3) regulates expression of paneth cell lineage-specific genes in intestinal epithelial cells through both TCF4/β-catenin-dependent and -independent signaling pathways
Brodrick, B., Vidrich, A., Porter, E., Bradley, L., Buzan, J. M. & Cohn, S. M., May 27 2011, In: Journal of Biological Chemistry. 286, 21, p. 18515-18525 11 p.
Research output: Contribution to journal › Article › peer-review
16 Scopus citations
Colitis causes delay in puberty in female mice out of proportion to changes in leptin and corticosterone
DeBoer, M. D., Li, Y. & Cohn, S., Mar 2010, In: Journal of Gastroenterology. 45, 3, p. 277-284 8 p.
Research output: Contribution to journal › Article › peer-review
25 Scopus citations
Elevated expression of Paneth cell CRS4C in ileitis-prone SAMP1/YitFc mice: Regional distribution, subcellular localization, and mechanism of action
Shanahan, M. T., Vidrich, A., Shirafuji, Y., Dubois, C. L., Henschen-Edman, A., Hagen, S. J., Cohn, S. M. & Ouellette, A. J., Mar 5 2010, In: Journal of Biological Chemistry. 285, 10, p. 7493-7504 12 p.
Research output: Contribution to journal › Article › peer-review
15 Scopus citations
Epithelial cell apoptosis facilitates Entamoeba histolytica infection in the gut
Becker, S. M., Cho, K. N., Guo, X., Fendig, K., Oosman, M. N., Whitehead, R., Cohn, S. M. & Houpt, E. R., Mar 2010, In: American Journal of Pathology. 176, 3, p. 1316-1322 7 p.
Research output: Contribution to journal › Article › peer-review
31 Scopus citations

Steven Cohn, MD, PhD

Fingerprint

Network

Dive into details

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo and Active Controlled, Treat-Through study to Evaluate the Efficacy and Safety of Mirikizumab in Patients with Moderately to Severely Active Crohn's Disease

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo and Active Controlled, Treat-Through study to Evaluate the Efficacy and Safety of Mirikizumab in Patients with Moderately to Severely Active Crohn's Disease

Protocol I6T-MC-AMBG (a) A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis - LUCENT 2

Protocol I6T-MC-AMBG (a) A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis - LUCENT 2

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients with Moderately to Severely Active Ulcerative Colitis.

AIDS-associated Esophageal Plasmablastic Lymphoma

Fibroblast growth factor receptor-3 (FGFR-3) regulates expression of paneth cell lineage-specific genes in intestinal epithelial cells through both TCF4/β-catenin-dependent and -independent signaling pathways

Colitis causes delay in puberty in female mice out of proportion to changes in leptin and corticosterone

Elevated expression of Paneth cell CRS4C in ileitis-prone SAMP1/YitFc mice: Regional distribution, subcellular localization, and mechanism of action

Epithelial cell apoptosis facilitates Entamoeba histolytica infection in the gut

Steven Cohn, MD, PhD

Fingerprint

Network

Projects

Research output